THERAPEUTIC AGENT FOR HEPATITIS C
    1.
    发明申请
    THERAPEUTIC AGENT FOR HEPATITIS C 审中-公开
    乙型肝炎治疗药物C

    公开(公告)号:US20110200554A1

    公开(公告)日:2011-08-18

    申请号:US13124584

    申请日:2009-10-16

    摘要: A novel therapeutic agent for hepatitis C having a high therapeutic effect against hepatitis C is disclosed. The therapeutic agent for hepatitis C contains as an effective ingredient hydroxyurea. The therapeutic agent for hepatitis C optionally further contains interferon α. By the present invention, a novel therapeutic agent for hepatitis C having a high therapeutic effect against hepatitis C was provided. A synergistic therapeutic effect against hepatitis C is obtained by using interferon α in combination. Therefore, in cases where a patient is infected with the genotype of hepatitis C virus for which therapy by interferon α is effective, the therapeutic effect is further promoted by using interferon α in combination.

    摘要翻译: 公开了一种对丙型肝炎具有高治疗效果的新型丙型肝炎治疗剂。 丙型肝炎治疗剂含有羟基脲的有效成分。 丙型肝炎治疗剂任选地还含有干扰素α。 通过本发明,提供了一种对丙型肝炎具有高治疗效果的新型丙型肝炎治疗剂。 通过组合使用干扰素α获得对丙型肝炎的协同治疗效果。 因此,在患者感染了通过干扰素α治疗的丙型肝炎病毒基因型有效的情况下,通过组合使用干扰素α进一步促进了治疗效果。